This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Type of economic evaluation

Cost-utility analysis
Study objective
To assess the influence of the number of birth cohorts used in cost-effectiveness models under differential discounting using as an example a vaccination and/or screening strategy for human papillomavirus in women.
Interventions
The interventions under study were: addition of human papillomavirus (HPV) vaccination to cervical screening programmes; and a cervical screening programme. Screening was simulated as seven screens between ages 30 and 60 at five-year intervals (the Dutch programme). Vaccination was administered at age 12.
Location/setting
The Netherlands/Primary Care.
Methods
Analytical approach:
The published MISCAN model of cervical screening and HPV vaccination was used in the study by de Kok et al. (2009) (see Other Publications of Related Interest). The results of this model were compared between analyses with a single-cohort and with 10, 20 and 30 cohorts. Each cohort was defined by its year of birth and received the vaccination one year after the preceding cohort. The time horizon was the lifetime of the patient. The authors did not state the study perspective.
Effectiveness data:
Effectiveness data were the same as those in the de Kok study and compared HPV vaccination and screening with screening alone.
Monetary benefit and utility valuations:
Utility estimates were the same as those used in the de Kok study and compared HPV vaccination and screening with screening alone.
Measure of benefit:
The benefit measure was quality-adjusted life years (QALYs). Future benefits were discounted at an annual rate of 1.5%. In supplementary analyses, benefits were discounted at an annual rate of 4%. The direct costs included in the analysis were those used in the de Kok study and compared HPV vaccination and screening with screening alone. Future costs were discounted at an annual rate of 4%. Costs were reported in Euros (€).
Cost data:
Analysis of uncertainty:
A one-way sensitivity analysis was undertaken with costs discounted at an annual rate of 4%, effects discounted at an annual rate of 1.5% and a common annual discount rate of 4%.
Results
Discounting future costs at 4% per annum, the incremental costs of adding vaccination to the Dutch screening programme were: €324,423 million for a single cohort; €273,662 million for 10 birth cohorts; €229,268 million for 20 birth cohorts and €194,470 million for 30 birth cohorts.
Discounting future benefits at 1.5% per annum, the incremental QALYs gained from adding vaccination to the Dutch screening programme were 10,839,000 for a single cohort, 10,146,000 for 10 birth cohorts, 9,444,000 for 20 birth cohorts and 8,809,000 for 30 birth cohorts.
Discounting future benefits at 4% per annum, the incremental QALYs gained from adding vaccination to the Dutch screening programme were 3,190,000 for a single cohort, 2,690,000 for 10 birth cohorts, 2,254,000 for 20 birth cohorts and 1,912,000 for 30 birth cohorts.
Costs and benefits were combined using an incremental cost-utility ratio (additional cost per QALY gained). Using a 4% discount rate for both costs and benefits, the incremental cost per QALY gained of adding vaccination to screening was €101,700 irrespective of the number of cohorts used.
Using a 4% discount rate for costs and a 1.5% rate for benefits, the incremental cost-utility ratio of adding vaccination to screening was €29,900 for a single cohort, €27,000 for 10 cohorts, €24,300 for 20 cohorts and €22,100 for 30 cohorts.
